Fever News and Research

RSS

New polyclonal immunotherapy successfully neutralizes Ebola virus

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided "100% protection against a lethal dose of the Ebola virus" in a recent animal study published in The Journal of Infectious Diseases.

15 Aug 2018

Ebola outbreak in Congo spreads to active combat zone

The outbreak of the deadly Ebola in the Democratic Republic of Congo has spread outside the province of North Kivu according to a statement made by the country’s health ministry yesterday. With this the viral infection has reached an active conflict zone and this may mean that it could spread wider now.

14 Aug 2018

FDA approves first oral medication for treatment of adults with Fabry disease

The U.S. Food and Drug Administration today approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease.

10 Aug 2018

One-two punch of powerful antibodies may be best way to stop Ebola virus

A one-two punch of powerful antibodies may be the best way to stop Ebola virus, reports an international team of scientists in the journal Cell.

10 Aug 2018

Long term effects of Zika virus exposure during pregnancy studied

Zika is a mosquito borne virus that can be dangerous in pregnant women as it can cause severe congenital malformations and damage to the baby. The extent of danger however is not known and a large study followed children who were exposed to this virus during their time within the womb.

7 Aug 2018

Young children are more vulnerable to climate-related health risks, shows study

Young children are far more vulnerable to climate-related disasters and the onus is on adults to provide the protection and care that children need, according to research by Columbia University's Mailman School of Public Health and Columbia University Irving Medical Center.

7 Aug 2018

Unique experimental vaccine against Zika virus proves powerful in mice

A uniquely designed experimental vaccine against Zika virus has proven powerful in mice, new research has found.

6 Aug 2018

World's major heart surgery organizations call for effective strategies to treat rheumatic heart disease

Experts from the world's major heart surgery organizations-including The Society of Thoracic Surgeons, the American Association for Thoracic Surgery, the Asian Society for Cardiovascular and Thoracic Surgery, and the European Association for Cardio-Thoracic Surgery-are calling for urgent action to develop and implement effective strategies for treating rheumatic heart disease, which affects 33 million people and kills 320,000 annually.

3 Aug 2018

Scientists map regulatory landscape of mouse genome at single-cell resolution

Scientists have completed a major effort to map the regulatory landscape of the mouse genome at a single-cell resolution.

2 Aug 2018

European Commission approves Pfizer’s first oncology biosimilar

Pfizer Inc. today announced the European Commission has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

31 Jul 2018

Researchers describe strategy used by Oropouche virus to replicate in human cells

The strategy used by the Oropouche virus to replicate in human cells has been described for the first time by researchers at the University of São Paulo in Brazil and international collaborators in an article published in the journal PLOS Pathogens.

31 Jul 2018

World not ready to deal with a viral pandemic

A team of researchers from the John Hopkins Center for Health Security conducted a simulation with real life implications.

31 Jul 2018

Novartis' new drug combination receives positive CHMP opinion for treating stage III BRAF mutant melanoma

Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar® in combination with Mekinist® for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

27 Jul 2018

Eliminating malaria-carrying mosquitoes does not impact ecosystem, shows study

By combining studies on one species of malaria-carrying mosquito, researchers found that no other animals rely solely on them for food.

27 Jul 2018

Using a fan to cool down can worsen allergies like hayfever

Britain is facing a heat wave this week with maximum temperatures hovering around 34C. This heat may make sleeping comfortably at night difficult. To combat the heat many people turn on their fans to cool down as they sleep. Mark Reddick, wrote for Sleep Advisor and explained how the use of the fans at night can have a negative impact on health.

27 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Discovery of strange parasitic link to entrepreneurialism

Good news for cat lovers! A latest study has found that a parasite infestation found in cat feces could make a person an entrepreneur. Cat feces commonly contain parasite Toxoplasma gondii and its infection can often go unnoticed in most individuals. A new study has found that people who have had T. gondii infection are around 1.4 times more likely to major in business studies compared to those who were not infected.

25 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Study finds new enzyme that lays foundations for allergic immune response

While in search of the causes of allergies and asthma, a chance discovery has yielded new clues: researchers led by Dr Marcus Peters have ascertained that the enzyme guanylate cyclase in cells lays the foundations for the type of immune response.

23 Jul 2018

Pfizer announces FDA approval of biosimilar to Neupogen

Pfizer Inc. today announced that the United States Food and Drug Administration has approved NIVESTYM (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for all eligible indications of the reference product.

23 Jul 2018